In light of recent findings, would you consider prescribing dutasteride to men with low-risk prostate cancer to reduce their risk of PCa progression?

Share this article:

A randomized, double-blind study published recently in The Lancet showed that men on active surveillance for low-risk prostate cancer (PCa) who received the 5α-reductase inhibitor dutasteride for three years had a significant 38% decreased risk of PCa progression compared with men who took placebo. The investigators concluded that their findings “show that dutasteride could be a beneficial adjunct to active surveillance for men with low-risk prostate cancer, delaying their time to pathological progression and initiation of primary therapy.”

Renal & Urology News would like to ask its urologist readers the following question.


Leave a comment below to explain your choice.
Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Do you currently accept new Medicaid patients?

Do you currently accept new Medicaid patients?

The NHS has found that 31% of physicians were unwilling to accept new Medicaid patients.

How often do you try to persuade your patients who smoke to give up the habit?

How often do you try to persuade your ...

Doctors can play an important role in educating patients who smoke about the adverse health effects.

Is allowing patients direct access to lab results a good idea?

Is allowing patients direct access to lab results ...

A ruling from the HHS took effect allowing patients direct access to medical laboratory results.